Atezolizumab
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
- Atezolizumab
- Pharmacist Assessment Report
- Atezolizumab: PD-L1 inhibitor (monoclonal antibody) → uterine ligament adenocarcinoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Atezolizumab: PD-L1 inhibitor (monoclonal antibody) → uterine ligament adenocarcinoma
One-Sentence Summary
Atezolizumab is a monoclonal antibody drug that blocks PD-L1. The TxGNN model predicts it may be effective for uterine ligament adenocarcinoma, but no clinical trials and no publications directly studying this disease were found in the data compiled for this report, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | uterine ligament adenocarcinoma |
| TxGNN Prediction Score | 0.9993 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Atezolizumab is generally understood to be an anti-PD-L1 antibody, which can release the brake that PD-L1 places on T cells and so restore immune attack on tumour cells.
Uterine ligament adenocarcinoma is a gynaecological adenocarcinoma. A plausible link is PD-L1 blockade in this tumour type, but this is speculative and is not supported by any trial or publication in the data compiled for this report. The similarity between the original and predicted indications has not yet been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
For context only, two trials of atezolizumab in cervical cancer were found under a different, lower-ranked prediction (endocervical carcinoma). They do not study uterine ligament adenocarcinoma and are not counted as evidence for this prediction.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11277M | Tecentriq | Solution concentrate for I.V. infusion 1200 mg in 20 mL | Not recorded in the local data |
Safety Considerations
- Drug Interactions: 75 interacting drugs are recorded. Examples include:
- Major: adalimumab, baricitinib, BCG live (Tice substrain) antigen.
- Moderate: corticosteroids (hydrocortisone, prednisolone, prednisone, dexamethasone, methylprednisolone, budesonide, betamethasone, triamcinolone, deflazacort), roflumilast, azathioprine, alemtuzumab, anakinra, alefacept, and several vaccines (tetanus toxoid, anthrax, adenovirus type 4).
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but no clinical trial or publication directly studies uterine ligament adenocarcinoma, so the evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Literature and trial searches specific to uterine ligament adenocarcinoma, including related gynaecological adenocarcinomas
- Detailed mechanism of action data
- Warnings and contraindications from the TGA-approved Product Information
- Clinical expert review of whether the tumour type is biologically comparable to cancers where PD-L1 blockade is already used
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.